Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker

09 Apr 20264 min read0 viewsJournal Feed

GIST

British Journal of Cancer, Published online: 09 April 2026; doi:10.1038/s41416-026-03394-1 Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker

Clinical Editorial

Summary

British Journal of Cancer published a clinical update in Oncology on 09 Apr 2026.

The item focuses on Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Nat Rev OncRelated by Conditionmelanoma

Synergistic integration of regional and systemic therapies in uveal melanoma

Oncology • 29 Apr 2026

ClinicalTrialsRelated by Conditionmelanoma

Pilot Study of Spatially Fractionated Radiation Therapy in Extra-Cranial Soft Tissue Metastases

Oncology • 30 Mar 2026

ClinicalTrialsRelated by Conditionmelanoma

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Oncology • 24 Mar 2026

Br J CancerRelated by Conditionmelanoma

STAT3 signaling mediates EGFR-TKI resistance in non-small cell lung cancer by regulating stemness markers and telomerase, reversed by icaritin

Oncology • 22 Apr 2026

Br J CancerRelated by Conditionmelanoma

STAT3 signaling mediates EGFR-TKI resistance in non-small cell lung cancer by regulating stemness markers and telomerase, reversed by icaritin

Oncology • 22 Apr 2026

Nat Rev OncRelated by Conditionmelanoma

Cultivating the microbiome to enhance cancer immunotherapy

Oncology • 09 Apr 2026

Feed Metadata

Source

British Journal of Cancer